Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Tests of association for rare variants: case control mutation screening.

Tavtigian SV, Hashibe M, Thomas A.

Nat Rev Genet. 2011 Mar;12(3):224. doi: 10.1038/nrg2867-c1. Epub 2011 Feb 1. No abstract available.

2.

Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.

James PA, Harris M, Lindeman GJ, Mitchell G.

J Med Genet. 2008 Nov;45(11):765-6. doi: 10.1136/jmg.2008.061903. No abstract available.

PMID:
18978334
3.

Screening for Genetic Testing in Breast Cancer - Are We Missing the Full Picture?

McCormick G, Mikropoulos C, Sadler G, Abson C, Davis A, Hall J.

Clin Oncol (R Coll Radiol). 2016 Mar;28(3):226. doi: 10.1016/j.clon.2015.07.003. Epub 2015 Aug 5. No abstract available.

PMID:
26254840
4.

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

Bonadona V, Sinilnikova OM, Lenoir GM, Lasset C.

J Natl Cancer Inst. 2002 Oct 16;94(20):1582-3; author reply 1583-4. No abstract available.

PMID:
12381714
5.

Pitfalls and caveats in BRCA sequencing.

Bellosillo B, Tusquets I.

Ultrastruct Pathol. 2006 May-Jun;30(3):229-35. Review.

PMID:
16825125
6.

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.

7.

Epigenetic test for breast cancer.

Burki TK.

Lancet Oncol. 2014 Aug;15(9):e366. No abstract available.

PMID:
25225690
8.

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G.

J Clin Oncol. 2002 Jun 1;20(11):2701-12.

PMID:
12039933
9.

A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.

van der Hout AH, van den Ouweland AM, van der Luijt RB, Gille HJ, Bodmer D, Br├╝ggenwirth H, Mulder IM, van der Vlies P, Elfferich P, Huisman MT, ten Berge AM, Kromosoeto J, Jansen RP, van Zon PH, Vriesman T, Arts N, Lange MB, Oosterwijk JC, Meijers-Heijboer H, Ausems MG, Hoogerbrugge N, Verhoef S, Halley DJ, Vos YJ, Hogervorst F, Ligtenberg M, Hofstra RM.

Hum Mutat. 2006 Jul;27(7):654-66.

PMID:
16683254
10.

BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.

Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.

Ann Oncol. 2006 Jun;17 Suppl 7:vii34-40.

PMID:
16760289
11.

Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.

Meindl A; German Consortium for Hereditary Breast and Ovarian Cancer.

Int J Cancer. 2002 Feb 1;97(4):472-80.

12.

Mutations of BRCA genes in hereditary breast and ovarian cancer.

Radice P.

J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):9-12. Review.

PMID:
12585647
13.

Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.

Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, El May A, Revillion F, Peyrat JP.

Bull Cancer. 2014 Nov;101(11):E36-40. doi: 10.1684/bdc.2014.2049.

PMID:
25418591
14.

New test simplifies genetic testing for breast cancer.

Bosch X.

BMJ. 2002 Mar 30;324(7340):755. No abstract available.

15.

Supreme Court ruling broadens BRCA testing options.

Azvolinsky A.

J Natl Cancer Inst. 2013 Nov 20;105(22):1671-2. doi: 10.1093/jnci/djt342. Epub 2013 Nov 6. No abstract available.

PMID:
24198329
16.
17.

Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA.

Cancer Causes Control. 2005 Aug;16(6):667-74.

PMID:
16049805
18.

US panel rejects routine use of BRCA cancer screening in women.

McCarthy M.

BMJ. 2013 Apr 4;346:f2160. doi: 10.1136/bmj.f2160. No abstract available.

PMID:
23558348
19.

BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.

Marchina E, Fontana MG, Speziani M, Salvi A, Ricca G, Di Lorenzo D, Gervasi M, Caimi L, Barlati S.

Oncol Rep. 2010 Dec;24(6):1661-7.

PMID:
21042765
20.

Counseling the at risk patient in the BRCA1 and BRCA2 Era.

Barnes-Kedar IM, Plon SE.

Obstet Gynecol Clin North Am. 2002 Jun;29(2):341-66, vii. Review.

PMID:
12108833

Supplemental Content

Support Center